title: Serodeconversion of HIV antibody-positive AIDS patients following treatment with V-1 Immunitor.
abstract: It is extremely rare when HIV seropositive adult patients experience spontaneous loss of antibodies, that is, seroreversion. The disappearance of HIV antibodies was occasionally attributed to iatrogenic intervention-serodeconversion. Such interventions include: HAART; oral interferon; Chinese herbal remedies; and therapeutic AIDS vaccines derived from pooled blood. Oral therapeutic, alloimmune AIDS vaccine, V-1 Immunitor (V1), was administered to 60000 HIV-positive Thai patients. The administration of V1 resulted in serodeconversion among 23 individuals. The patient group consisted of 9 females (39%) and 14 males (61%) including two 2-year-old boys. The age range was 2-58 years with mean/median 29/29.3 years. Patients were tested seropositive for HIV at least once before being enrolled on V1. The duration of treatment until discovery of seronegative status ranged between 2 weeks and 15 months with average/median 7.2/8 months. Time to seronegativity was correlated with baseline disease stage (R = 0.62; P = .002). The seronegative status was positively associated with V1-induced undetectable or low viral load (R = 0.65; P = .0008). The odds ratio analysis comparing the outcome of our study with published surveys of diagnostic accuracy of laboratory tests suggested that the probability of HIV antibody testing error was remote (P < .000001). The possible causes responsible for this unusual phenomenon are discussed.
authors.affiliation: Occupational and Environmental Medicine Association of Thailand, Rajavithi General Hospital, Ministry of Public Health, Bangkok 10400, Thailand.
authors.forename: Orapun
authors.initials: O
authors.lastname: Metadilogkul
authors.forename: Vichai
authors.initials: V
authors.lastname: Jirathitikal
authors.forename: Aldar S
authors.initials: AS
authors.lastname: Bourinbaiar
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy* / Q000821:virology; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013785:Thailand; D019562:Viral Load; D055815:Young Adult
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; C452261:V-1 Immunitor